Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma.

Trial Profile

An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004072).
    • 09 Jun 2009 Actual end date changed from Oct 2008 to Nov 2008 as reported by ClinicalTrials.gov.
    • 30 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top